Last reviewed · How we verify

NCT06646523

Effects of Home-based High-speed Bodyweight Resistance Training in Individual With Parkinson's Disease

Recruiting now NA Last updated 27 February 2026
What this trial tests

NA trial testing High-speed bodyweight resistance training in Parkinson Disease in 46 participants. Currently enrolling.

Timeline
18 October 2024
Primary endpoint
31 March 2026
31 March 2026

Quick facts

Lead sponsorFederal University of Minas Gerais
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment46
Start date18 October 2024
Primary completion31 March 2026
Estimated completion31 March 2026
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Federal University of Minas Gerais

Who can join

50 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exercises that involve increasing the speed of movements are beneficial for individuals with Parkinson's disease (PD) and have the potential to reduce bradykinesia and improve mobility. High-speed bodyweight resistance training is a treatment that involves increasing speed considered accessible and viable as it can be performed at any time and place, including at home. This treatment has already shown benefits in the elderly individuals, however no studies were found in individuals with PD. Therefore, the primary aim of this study will be to investigate the effects of home-based and remotely supervised high-speed bodyweight resistance training in reducing bradykinesia in individuals with PD. The secondary aim will be to investigate the effects of home-based and remotely supervised high-speed bodyweight resistance training in improving mobility, muscle power, dynamic balance, and quality of life in this population. A randomized controlled trial will be carried out with concealed allocation, blinded assessments, and intention-to-treat analysis. Altogether, 46 individuals with PD (age ≥ 50 years old, who are bradykinetics and sedentary or insufficiently active will be included. Participants will be randomly assigned to either an experimental group (high-speed bodyweight resistance training) or a control group (bodyweight intervention, usual speed). Both groups will perform a home-based and remotely supervised intervention, consisting of 60-min individual sessions, three times per week over 12 weeks, with a trained physiotherapist. Primary outcomes is bradykinesia of the lower limbs. Secondary outcomes are mobility, muscle power, dynamic balance, and quality of life. The findings of this trial have the potential to provide important insights regarding the effects of high-speed bodyweight resistance training in reducing bradykinesia and improving mobility in individuals with PD. High-speed bodyweight resistance training does not use any type of external resistance and can be performed anywhere and at any time. In addition, it can be performed at home through telemonitoring, reducing time and costs of transport, making it quite feasible and accessible for individuals from different social and economic backgrounds which increases the feasibility of reproducing their findings in clinical practice.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of Remotely Supervised Home-Based High-Speed Bodyweight Resistance Training on Bradykinesia in Individuals With Parkinson Disease: Protocol for a Randomized Controlled Trial.
    Benfica PDAY, Scianni AA, Soares CLA, Ribeiro IL, et al · · 2026 · PMID 42082175 · DOI 10.2196/84689

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other Federal University of Minas Gerais trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06646523.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing